16 Jul
2021

Biden’s march-in rights reversal is further evidence of US policy shift on pharma IP rights

Following support for the proposed TRIPS waiver, the new administration has abandoned Trump-era proposals to rule out patent suspension under the Bayh-Dole Act

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth